Vincenzo Di Marzo to lead GW’s pre-clinical research
Leading cannabinoid scientist joins cannabis medicine specialist
Professor Di Marzo is a leading cannabinoid scientist, co-author of more than 460 peer-reviewed publications, and in 2010 was recognised as Thompson Reuters 'top scientist of the decade' for pharmacology and toxicology.
He has previously served as president of the International Cannabinoid Research Society (ICRS) and is a recipient of ICRS’s Mechoulam Award for ‘outstanding contributions to cannabinoid research’.
Professor Di Marzo is a research director at the Institute of Biomolecular Chemistry of the National Research Council (ICB-CNR) in Pozzuoli, Naples, Italy, coordinator of the Endocannabinoid Research Group in the Naples region, and an adjunct associate professor in the Department of Pharmacology and Toxicology at the Medical College of Virginia at Virginia Commonwealth University in Richmond.
In his new engagement with GW Pharmaceuticals, Professor Di Marzo will be responsible for coordinating the research efforts of GW’s global network of cannabinoid scientists. This network now extends to more than 25 academic institutions in 11 countries and involves research in a wide range of therapeutic areas, including oncology, neuroscience, metabolic disease, inflammatory disease, gastroenterology, and dermatology. The objective of this research effort is to progress a number of GW’s new cannabinoid pipeline candidates to full clinical development.
You may also like
Manufacturing
Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market
Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA
Ingredients
Pangea Pharmaceuticals launches FDA-approved amlodipine oral solution Sdamlo
Pangea’s Sdamlo, the first FDA-approved amlodipine powder for oral solution, leverages a patent-pending lyophilisation process to enable precise unit-dose delivery and improved administration for paediatric, geriatric and dysphagic patients
Ingredients
Oncodesign Services extends GIP ARRONAX collaboration to secure astatine-211 supply
The company has extended its collaboration with the French radionuclide specialist to secure access to astatine-211, an alpha-emitting radioisotope of growing interest in targeted radiotherapy but constrained by its seven-hour half-life and limited production capacity